Latest milestones
Biologics milestone tracker
- Rybrevant Faspro · head and neck cancerFDA granted accelerated approval for eligible adults with recurrent or metastatic disease after platinum and PD-(L)1 therapy.
- Jemperli · rectal cancerFDA granted accelerated approval for the biomarker-defined rectal cancer indication.
Headlines
7 in this edition-
FDA forms a safety council to follow biologics after approval
The council will oversee postmarket safety across CBER products, including cell and gene therapies and blood products.
FDAOptions
-
Infilbray wins approval for neurological symptoms of type 3 Gaucher disease
FDA cleared venglustat for adults and children weighing at least 15 kg after a study compared it with enzyme replacement therapy.
FDAOptions
-
FDA clears Lembaz for infantile-onset Niemann-Pick type C
The indication covers reducing mortality risk in patients weighing at least 7 kg whose neurological symptoms began before age six.
FDAOptions
-
Rybrevant Faspro gains a head and neck cancer indication
FDA granted accelerated approval after prior platinum chemotherapy and PD-(L)1 treatment, excluding HPV-associated oropharyngeal tumors.
FDAOptions
-
FDA grants accelerated approval for Jemperli in a subset of rectal cancers
The new indication covers adults with stage II or III locally advanced tumors that are MSI-high or mismatch-repair deficient.
FDAOptions
-
Glycogen storage disease trial posts its phase 3 results
The DTX401-CL301 registry record now includes the results tables underlying the program’s evaluation of daily cornstarch intake.
ClinicalTrials.govOptions
-
Fayuvi gains approval for pediatric Sanfilippo syndrome type A
The indication covers neurological manifestations in children whose neurodevelopmental function is preserved.
FDAOptions
No matching headlines.